Short Interest in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Drops By 43.3%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 622 shares, a drop of 43.3% from the February 26th total of 1,097 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 1,322 shares, the short-interest ratio is currently 0.5 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Shares of Amplify Weight Loss Drug & Treatment ETF stock traded down $0.01 during mid-day trading on Friday, hitting $23.66. 115 shares of the stock were exchanged, compared to its average volume of 2,631. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $18.56 and a 12 month high of $27.28. The company has a 50-day simple moving average of $25.48 and a 200 day simple moving average of $24.91. The company has a market capitalization of $3.55 million, a P/E ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Announces Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were given a dividend of $0.4132 per share. This represents a dividend yield of 162.0%. The ex-dividend date of this dividend was Tuesday, December 30th.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.